Physician profile
Michael L Silverman
NPI 1134112931
$8,071.11
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,661 · 2020: $1,157 · 2021: $751 · 2022: $503.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $6,077.58 | 2019-2022 | |
| Viiv Healthcare Company | $1,019.21 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $446.86 | 2019-2022 | |
| Janssen Biotech, INC. | $322.87 | 2019-2022 | |
| Janssen Products, LP | $99.95 | 2019 | |
| Emd Serono, INC. | $63.59 | 2019 | |
| Theratechnologies INC. | $25.35 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.70 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.